Preserving mobility, independence and healthspan with muscle intelligence.
Scalable muscle intelligence to support clinical care.
Elaya is building a first-of-its-kind muscle intelligence platform enabling objective measurement of muscle function in clinical environments.
Muscle health is a primary determinant of recovery, mobility, and long-term outcomes, yet it remains largely unmeasured in clinical practice.
This results in missed intervention windows, inefficient care delivery, and significant downstream costs.
Measuring muscle health in the ICU
What is ICU-acquired weakness
Muscle at ICU admission (light grey)
Same muscle 6 months post-ICU discharge
Patients ventilated and sedated in the ICU are most at risk of developing ICU-acquired weakness. Muscle loss can progress as quickly as 2-4% per day. 50% of patients 65 or older, on a ventilator in the ICU for a week or more experience permanent disability.
Prevention of ICU-acquired weakness can reduce ICU stay by up to 4 days, preserve mobility and function and enable the return to active life after recovery.
Increased health care costs as a result of longer ICU stay and functional dependence post-ICU discharge.
About Us
Elaya’s mission is to preserve mobility, independence and healthspan for patients through muscle intelligence. We give clinicians the tools and insight they need to identify problems early, develop personalized care plans and deploy resources most effectively.
By integrating proprietary sensors, automated data processing, and digital biomarkers, Elaya transforms muscle health into a quantifiable, actionable vital sign, unlocking a new category in healthcare data.
Partners
